Subcutaneous ocrelizumab (SC OCR) maintains a safety profile similar to intravenous administration in multiple sclerosis patients. A 920 mg SC OCR dose was identified as optimal, with mild to ...

Treating multiple sclerosis (MS) with monoclonal antibodies ... Following this, the newer anti-CD20 mAbs ocrelizumab and ofatumumab, which are currently being tested in Phase II for MS, are ...

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

Anti-CD20 agents: B lymphocyte depletion: Rituximab no longer being pursued for multiple sclerosis (MS) indication. Ocrelizumab Phase II with positive results, several Phase III underway.

According to the MS Society, certain medications like ocrelizumab (Ocrevus) can slow the progression of the disease in primary progressive multiple sclerosis, and syponimod (Mayzent) can help with ...

If you have multiple sclerosis (MS) and are hoping to get ... Monoclonal antibodies, which include drugs like ocrelizumab (Ocrevus) and ofatumumab (Kesimpta), have even longer waiting periods ...

Ocrelizumab is an intravenous (IV) infusion medication used to treat certain types of multiple sclerosis (MS) and clinically isolated syndrome. Interaction result: Taking Tecfidera with ...

Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), reaching CHF 60.5bn ($66.9bn). The ...

Multiple sclerosis (MS) is a disease that looks different ... Nearly half of them have chosen to be on ocrelizumab (brand name Ocrevus), a monoclonal antibody infusion that's given twice a year.